Belimumab treatment for systemic lupus erythematosus
Part of Immune system & allergy, Skin clinical trials.
This study looks at how well belimumab works in people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. It aims to see if the treatment helps, regardless of how well it worked in the past.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a diagnosis of systemic lupus erythematosus (SLE) based on standard criteria or your doctor's judgment.
- You must have received at least one dose of belimumab, either as an injection under the skin or through an IV, as decided by your doctor.
- You must agree to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medications, telitacicept and belimumab, to see which is safer and more effective for treating lupus. It might help you if standard treatments haven't worked well for you.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This study looks at how the drug belimumab affects the long-term course of lupus. It compares patients who receive belimumab to similar patients who do not, to see if it helps control disease activity over time.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.